Prime Medicine, Bristol Myers Squibb
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
N ext-generation healthcare company Prime Medicine (NASDAQ: PRME) was exactly what the doctor ordered for ailing portfolios on the first trading day of the week. On a company upda
Prime Medicine stock rallies 15% on Bristol Myers deal, drug updates
Prime Medicine (NASDAQ:PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers Squibb (NYSE:BMY), which includes a $55M equity investment. Under the deal, Prime (PRME) will receive $55M upfront and the $55M investment.
Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is rarely straightforward.
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
Prime Medicine soars as it inks research collab with BMS
Cambridge, USA-based Prime Medicine saw its shares rocket more than 38% to $4.78 today, as it revealed a strategic research collaboration and license agreement with Bristol Myers Squibb.
Prime Medicine Inks Up-to-$3.5B Collaboration with BMS, Narrows Pipeline
Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more than $3.
Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb
Prime Medicine, Inc. (PRME) announced Monday a strategic research collaboration and license agreement with Bristol Myers Squibb (BMY)
Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb
Prime Medicine shares rose on Monday after the company signed a research collaboration and license agreement Bristol Myers Squibb to develop reagents for T-cell therapies. In premarket trading, shares were up 20% to $4.
Prime Medicine Unveils Strategically Focused Pipeline
Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime ...
FierceBiotech12h
BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline
Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...
STAT10h
A radiopharmaceuticals startup raises $175 million
RA Capital, RTW Investments, Janus Henderson Investors are pouring another $175 million into a radiopharmaceuticals startup.
BioSpace4h
Gene Editor Prime Medicines Signs BMS Cell Therapy Deal, Reprioritizes Pipeline
In an effort to expand its cash runway beyond 12 months, Prime Medicines has signed a deal with Bristol Myers Squibb worth a ...
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
Consumer staples shares jumped by 0.3% on Monday. In trading on Monday, materials shares fell by 0.6%. In commodity news, oil ...
bovnews2d
The PRME Stock Mystery: Why Did PRME Plunge Today?
On Friday, Prime Medicine Inc (PRME) stock saw a decline, ending the day at $3.46 which represents a decrease of $-0.10 or -2.81% from the prior close of $3.56. The stock opened at $3.62 and touched a ...